The research article represents the culmination of research collaborations involving leading antimicrobial researchers across the world.
’s () (OTCMKTS:BXPHF) has had research data from its antimicrobial platform published in Nature Research’s peer-reviewed journal, Communications Biology.
The research article titled ‘The antimicrobial potential of cannabidiol’ has been released via open access and describes for the first time that synthetic cannabidiol can also kill a select group of Gram-negative bacteria, including the bacteria responsible for gonorrhoea, meningitis and legionnaires disease.
This article represents the culmination of research collaborations involving leading antimicrobial researchers across the world and all research data generated is fully-owned by Botanix and is the subject of several patent applications.
“Establishes Botanix as world leader”
Botanix president and executive chairman Vince Ippolito said: “The published data clearly establishes Botanix as the world leader in characterising and exploiting the pharmaceutical potential of synthetic cannabinoids as antimicrobials – and vast potential for the development of novel and effective treatments.
“Congratulations to all the collaborators involved in this significant body of research.”
Phase 2a antimicrobial study completed
Botanix has also completed the BTX 1801 antimicrobial clinical study and is on track to announce data in the current quarter.
The study aims to test the ability of the nasally applied BTX 1801 ointment to eradicate Staphylococcus aureus and methicillin-resistant Staphylococcus aureus (MRSA) from the nose of individuals known to carry these bacteria in their nasal cavity.
Nasal ‘carriage’ of Staph and/or MRSA greatly increases the risks of serious and sometimes life-threatening infections following surgery, as patients essentially infect themselves.
Nasal decolonisation is a commonly used method for preventing SSIs, but overuse of the widely available antibiotic BactrobanTM (also known as mupirocin) has led to a significant increase in the development of bacterial resistance to antibiotics.
The double-blind, vehicle-controlled BTX 1801 Phase 2a clinical study has been designed to evaluate the safety and local tolerability of two formulations of BTX 1801 to decolonise Staph and MRSA (or Golden Staph) from the nose of healthy adults.
